Arvinas arvinas.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients. To address these pathological intracellular proteins, Arvinas is developing a new drug paradigm based on t...Show all

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer ...Show all

Company (IPO / Went public)

Phone: 860-463-2249

Fax:

5 Science Park
395 Winchester Avenue
New Haven, 06511
Connecticut, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Arvinas $234.9M Sep 27, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Arvinas Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors
There is no Competitors data available for this company. Please select another tab.